---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003889"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:48:35.514192+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# KALA BIO raises $8.6M in private placement of Series G convertible preferred stock

## Summary
- Gross proceeds of $8.6 million from sale of 10,901 Series G Preferred shares at $788.90 each.
- Each Series G share initially convertible into 100 common shares, subject to 9.99% beneficial ownership limitation.
- Closing expected on March 26, 2024; offering exempt under Section 4(a)(2) and Regulation D.
- Company filed Certificate of Designations with Delaware establishing Series G Preferred Stock terms.

## SEC filing metadata
- accession: 0001558370-24-003889
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/0001558370-24-003889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/kala-20240325x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003889
- JSON: https://secwatch.observer/filing/0001558370-24-003889.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003889.txt

## Key facts
- Governance Changes
  KALA BIO, Inc.: Filed Certificate of Designations for Series G Convertible Non-Redeemable Preferred Stock (effective 2024-03-25).
  - Change: charter amendment
  - Effective: 2024-03-25
  source text: On March 25, 2024 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series G Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series G Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/0001558370-24-003889-index.htm
- Material Agreements
  KALA BIO, Inc. entered into Securities Purchase Agreement with certain institutional investors named therein valued at aggregate gross proceeds of approximately $8.6 million (effective 2024-03-25).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors named therein
  - Value: aggregate gross proceeds of approximately $8.6 million
  - Effective: 2024-03-25
  source text: On March 25, 2024, KALA BIO, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement priced at-the-market under Nasdaq rules, shares (the “Preferred Shares”) of Series G Convertible Non-Redeemable Preferred Stock, par value $0.001 per share, of the Company (the “Series G Preferred Stock”), for aggregate gross proceeds of approximately $8.6 million (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837024003889/0001558370-24-003889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.